UK markets close in 4 hours 42 minutes

COMPASS Pathways plc (CMPS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.90+0.15 (+1.40%)
At close: 04:00PM EDT
10.90 0.00 (0.00%)
Pre-market: 05:32AM EDT
Sign in to post a message.
  • R
    Richard
    what games are being played after hours?
  • A
    Anonymous
    8%+ after hours. phase 3 coming???
  • J
    Joe
    Phase 3 is to start in the middle of 2023.
  • S
    Sweet
    when will it start phase 3
  • W
    Waxingeloquence
    $CMPS This weeks psychedelic sector recap is filled with patent news, I get into Mindmed and Compass Pathways recent successes regarding their respective patent journeys. Things are getting spicy!!
    https://youtu.be/WayHr_aRBj4
  • R
    Roger
    Phase 3 announcement soon?
  • S
    Sebastian
    I’m writing from Cape Town South Africa, this week alone I had 5 people ask me my opinion on CMPS. I think there’s real interest in the stock but it’s also the first time South Africans have been offered the convenience of an e-trading platform like SwisssQuote to trade these less than mainboard stocks. We know what psilocybin can do and we love that we can invest in companies that are committed to bringing this healing medicine to the millions who’ll benefit. It’s also a teacher medicine that can significantly enhance the brain function and well being of those who don’t have mental illness. Mental wellness in my view is where CMPS has the potential to expand the target market for treatment from 400m to +4bn.
  • S
    Steve
    with an N of 75 and 4 dropped out, at the 25mg dosage the difference was significant at the .001 level. That is huge but it is still phase 2.
  • W
    Waxingeloquence
    ** I had to take down the first video posted as it was uploaded incomplete, this new version that is uploaded is complete, my apologies.**

    In the new Psychedelic Invest episode I give an updated comparison of the financials of $ATAI, $MNMD and $CMPS as of Q1 2022 ER's. I also give a much more comprehensive breakdown of the pipelines of each company. Lastly I touch on Delix and what we can expect with next gen psychedelics.
    https://youtu.be/e67B_xXs-j0
  • R
    Romeo
    I know this might be old news for some but I read over the weekend that compass pathways clinical trial for depression using psychedelics was only 25% effective? Is this true??
  • R
    Roger
    It's good to see investors noticing CMPS' good ER and update. Reduced operating costs, $243M cash and on pace to start Phase III later this year. . . My question is: if CMPS has a cash runway of 2 years, why did they open the door to an ATM? Is this just to give them the option if needed? Or are they planning on expanding into trials of anorexia and autism and would need more cash? It seems like bad timing with SP down a lot, yet in the long run could be a positive.
  • D
    DB
    dilution incoming...hoping the added liquidity helps us fight the shorts. https://ir.compasspathways.com/static-files/5d772372-7c45-48f2-b620-e7b69790c729
  • R
    Roger
    CMPS is now trading at book value
  • B
    Bryn
    There’s something going on here that’s for sure. This legal challenge against the patent seems to be the driving force. I’m not an expert on patents but logically what Compass is doing is taking psylocibin which it’s not possible to take in measured form in its natural state. Compass has not only found a way to make every dose measurable and exactly the same but has tested this dose in a clinical setting. That’s a huge amount of work and research. If the FDA approves the results and gives the green light it is separate to the patent. They’re not judging the validity of the patent, rather it’s efficacy. Which seems promising. The legal action is therefore putting pressure on the foundations of Compass business model which knocks on to its share price (value). Even with FDA approval this legal challenge hangs around, right. However what bugs me is why challenge a drug which has been formulated in such a way that it can be regulated and brought to market to help a lot of people? It’s not as though Compass are trying to take ownership of psylocibin as people can grow it if they want and have done for a long time. So the basis for the legal attack seems suspect to me. It doesn’t stack up. So the question has to be asked as to whether those taking legal action are funding and monetising their attack though short selling. If that’s the case sooner or later there will be a short squeeze as there isn’t much money to be made short selling anymore with the share price where it is (low). Just a hunch but this company isn’t about to go bust (as one comment mentions) and has a runway of cash to take it through FDA approval if it’s thats possible. It’s not revenue generating - of course it isn’t, it’s not got FDA approval so that’s not the problem either. The big question here is whether legal action is an Elliot style hostile money making scheme. Elliot will go after underperforming established businesses rather than pre-revenue. So question is what’s going on here and only logical answer in my mind is that the legal action is not ‘for the greater good’ as it claims to be but rather a mechanism to make hostile shorting of the stock highly lucrative at shareholders expense (in the short term at least). I will hang on to see what the FDA says and if it’s good news price could rebound and squeeze out the shorts which compounds the rebound. Think Tesla.
  • K
    Ko
    Imagine buying at $57
  • J
    Joe
    When does the death of compass stop
  • D
    DEREK
    you can thank me I just bought in recently and already I'm a bag holder sorry 😞
  • O
    Omar
    They guided to having an FDA meeting in April to discuss the COMP360 Phase III trial—no news on this?
  • G
    G Ram
    Hello fellow bagholders!
  • D
    DB
    short sale restriction has kicked in - not sure what this is all about - positive news from Oregon today and still a sectoral rout on an overall green day.